KV To Pay $28M Over Ethex Drug Safety Charges

Law360, New York (February 25, 2010, 6:11 PM EST) -- KV Pharmaceutical Co. has agreed to pay $27.6 million to resolve U.S. Department of Justice charges that its generic pharmaceutical marketing and distribution subsidiary Ethex Corp. failed to notify regulators of drug safety problems.

Under the terms of the agreement KV Pharmaceutical disclosed Thursday, Ethex will plead guilty to two felony counts of failure to notify the U.S. Food and Drug Administration of significant problems with its hyperactivity treatment dextroamphetamine and its arrhythmia drug propafenone, once the company discovered that certain tablets failed to meet product...
To view the full article, register now.